RE:Tax loss deal?The game in the pharmaceutical industry has been going on for years. Freeze competition from entering your space through courts that drag out litigation for months sometimes years. The outcomes are never in question and the penalties are generally much less than the profits reaped during the litigation. Not sure what Cipher wants for the full transfer of rights back to Bausch but it must be large for both parties to be still battling this out. Cipher has spent close to 10 million on it and Bausch has seen it's a blockbuster north of the border which I'm sure Cipher is relishing in knowing how dearly Bausch wants this. It maybe worth a dollar a share alone add the tax losses and it makes sense for Bausch to just buy the whole company. May wait to see if Actavis launches a generic Absorica on the 27th of December. If they don't then Cipher can expect another year of unobstructed revenue from it from Sun.